



Biogen to Host Investor Webcasts from Clinical Trials on Alzheimer's Disease Meeting on October 25-26, 2018

October 4, 2018

Cambridge, Mass. – October 4, 2018 – [Biogen](#) (Nasdaq: BILB) today announced it will host live webcasts of its oral presentation and keynote address, as well as a Q&A session related to its Alzheimer's disease investigational therapies, at the upcoming Clinical Trials on Alzheimer's Disease annual meeting in Barcelona, Spain.

Webcast Details:

- Thursday, October 25, 7:30-8:00 a.m. ET / 1:30-2:00 p.m. CEST - *Keynote: What Have We Learned from Aducanumab?*
- Thursday, October 25, 4:15 p.m. ET / 10:15 p.m. CEST – *Investor Q&A call with Alfred Sandrock, Jr., M.D., Ph.D., executive vice president and chief medical officer at Biogen, and Samantha Budd Haeberlein, Ph.D., vice president, Alzheimer's disease, dementia and movement disorders, late stage clinical development at Biogen*
- Friday, October 26, 9:15-9:30 a.m. ET / 3:15-3:30 p.m. CEST - *Oral Presentation: Aducanumab Titration Dosing Regimen: 36-Month Analyses from PRIME, a Phase 1b Study in Patients with Early Alzheimer's Disease*

To access the live webcasts, please go to the Investors section of Biogen's website at [investors.biogen.com](#). Following the live webcasts, archived versions will be available on the website.

About Biogen

At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. One of the world's first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp, and today has the leading portfolio of medicines to treat multiple sclerosis; has introduced the first and only approved treatment for spinal muscular atrophy; and is focused on advancing neuroscience research programs in Alzheimer's disease and dementia, multiple sclerosis and neuroimmunology, movement disorders, neuromuscular disorders, pain, ophthalmology, neuropsychiatry and acute neurology. Biogen also manufactures and commercializes biosimilars of advanced biologics.

We routinely post information that may be important to investors on our website at [www.biogen.com](#). To learn more, please visit [www.biogen.com](#) and follow us on social media – [Twitter](#), [LinkedIn](#), [Facebook](#), [YouTube](#).

About Aducanumab

Aducanumab (BIIB037) is an investigational compound being studied for the treatment of early Alzheimer's disease. Aducanumab is a human recombinant monoclonal antibody (mAb) derived from a de-identified library of B cells collected from healthy elderly subjects with no signs of cognitive impairment or cognitively impaired elderly subjects with unusually slow cognitive decline using Neurimmune's technology platform called Reverse Translational Medicine (RTM). Biogen licensed aducanumab from Neurimmune under a collaborative development and license agreement. As of October 22, 2017, Biogen and Eisai are collaborating on the development and commercialization of aducanumab globally. In addition, the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development of aducanumab, a process allowing priority reviews by the FDA for drugs deemed as having potential to treat serious conditions and tackle key unmet medical needs.

###

MEDIA CONTACT:

David Caouette
+1 617 679 4945 ☐
public.affairs@biogen.com

INVESTOR CONTACT:

Matt Calistri
+1 781 464 2442 ☐
IR@biogen.com